Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shandong Lukang Pharmaceutical Co Ltd Announces FY 2012 Net Loss Outlook


Friday, 25 Jan 2013 07:00pm EST 

Shandong Lukang Pharmaceutical Co Ltd announced that it expects its net loss for fiscal year (FY) 2012 to be approximately RMB 135 million, compared to the net profit of FY 2011 (RMB 15,013,068.28). The Company cited the low price of its main products and decreasing price of veterinary antibiotics as the main reasons for the forecast. 

Company Quote

9.43
-0.35 -3.58%
31 Oct 2014